Eli Lilly Long Term Debt 1986-2025 | LLY

Eli Lilly long term debt from 1986 to 2025. Long term debt can be defined as the sum of all long term debt fields.
  • Eli Lilly long term debt for the quarter ending June 30, 2025 was $34.180B, a 44.04% increase year-over-year.
  • Eli Lilly long term debt for 2024 was $28.527B, a 55.71% increase from 2023.
  • Eli Lilly long term debt for 2023 was $18.321B, a 24.31% increase from 2022.
  • Eli Lilly long term debt for 2022 was $14.738B, a 3.97% decline from 2021.
Eli Lilly Annual Long Term Debt
(Millions of US $)
2024 $28,527
2023 $18,321
2022 $14,738
2021 $15,346
2020 $16,587
2019 $13,818
2018 $9,196
2017 $9,941
2016 $8,368
2015 $7,972
2014 $5,333
2013 $4,200
2012 $5,519
2011 $5,465
2010 $6,771
2009 $6,635
2008 $4,616
2007 $4,594
2006 $3,494
2005 $5,764
2004 $4,492
2003 $4,688
2002 $4,358
2001 $3,132
2000 $2,634
1999 $2,812
1998 $2,186
1997 $2,326
1996 $2,517
1995 $2,593
1994 $2,126
1993 $835
1992 $582
1991 $396
1990 $277
1989 $270
1988 $388
1987 $366
1986 $395
1985 $239
Eli Lilly Quarterly Long Term Debt
(Millions of US $)
2025-06-30 $34,180
2025-03-31 $34,500
2024-12-31 $28,527
2024-09-30 $29,045
2024-06-30 $23,730
2024-03-31 $24,560
2023-12-31 $18,321
2023-09-30 $17,924
2023-06-30 $18,158
2023-03-31 $18,881
2022-12-31 $14,738
2022-09-30 $14,144
2022-06-30 $14,692
2022-03-31 $15,153
2021-12-31 $15,346
2021-09-30 $15,522
2021-06-30 $14,737
2021-03-31 $16,200
2020-12-31 $16,587
2020-09-30 $16,335
2020-06-30 $15,064
2020-03-31 $13,982
2019-12-31 $13,818
2019-09-30 $13,662
2019-06-30 $13,718
2019-03-31 $13,610
2018-12-31 $9,196
2018-09-30 $11,675
2018-06-30 $9,171
2018-03-31 $9,394
2017-12-31 $9,941
2017-09-30 $9,927
2017-06-30 $9,868
2017-03-31 $7,638
2016-12-31 $8,368
2016-09-30 $8,707
2016-06-30 $8,686
2016-03-31 $7,478
2015-12-31 $7,972
2015-09-30 $8,070
2015-06-30 $7,989
2015-03-31 $7,415
2014-12-31 $5,333
2014-09-30 $5,293
2014-06-30 $5,301
2014-03-31 $5,255
2013-12-31 $4,200
2013-09-30 $4,264
2013-06-30 $4,291
2013-03-31 $4,432
2012-12-31 $5,519
2012-09-30 $5,511
2012-06-30 $5,500
2012-03-31 $5,403
2011-12-31 $5,465
2011-09-30 $5,451
2011-06-30 $5,200
2011-03-31 $5,132
2010-12-31 $6,771
2010-09-30 $6,982
2010-06-30 $6,862
2010-03-31 $6,661
2009-12-31 $6,635
2009-09-30 $6,770
2009-06-30 $6,688
2009-03-31 $6,871
2008-12-31 $4,616
2008-09-30 $4,186
2008-06-30 $4,546
2008-03-31 $4,648
2007-12-31 $4,594
2007-09-30 $4,532
2007-06-30 $4,574
2007-03-31 $4,624
2006-12-31 $3,494
2006-09-30 $4,553
2006-06-30 $5,578
2006-03-31 $5,613
2005-12-31 $5,764
2005-09-30 $5,881
2005-06-30 $4,446
2005-03-31 $4,357
2004-12-31 $4,492
2004-09-30 $4,511
2004-06-30 $3,532
2004-03-31 $4,504
2003-12-31 $4,688
2003-09-30 $4,998
2003-06-30 $4,862
2003-03-31 $4,787
2002-12-31 $4,358
2002-09-30 $4,363
2002-06-30 $3,499
2002-03-31 $3,383
2001-12-31 $3,132
2001-09-30 $3,154
2001-06-30 $2,898
2001-03-31 $2,657
2000-12-31 $2,634
2000-09-30 $2,785
2000-06-30 $2,797
2000-03-31 $2,783
1999-12-31 $2,812
1999-09-30 $2,816
1999-06-30 $1,979
1999-03-31 $1,982
1998-12-31 $2,186
1998-09-30 $2,269
1998-06-30 $2,308
1998-03-31 $2,337
1997-12-31 $2,326
1997-09-30 $2,344
1997-06-30 $2,502
1997-03-31 $2,510
1996-12-31 $2,517
1996-09-30 $2,582
1996-06-30 $2,587
1996-03-31 $2,576
1995-12-31 $2,593
1995-09-30 $2,118
1995-06-30 $2,102
1995-03-31 $1,639
1994-12-31 $2,126
1994-09-30 $1,174
1994-06-30 $1,173
1994-03-31 $855
1993-12-31 $835
1993-09-30 $940
1993-06-30 $786
1993-03-31 $780
1992-12-31 $582
1992-09-30 $436
1992-06-30 $442
1992-03-31 $444
1991-12-31 $396
1991-09-30 $496
1991-06-30 $286
1991-03-31 $235
1990-12-31 $277
1990-09-30 $275
1990-06-30 $271
1990-03-31 $269
1989-12-31 $270
1989-09-30 $268
1989-06-30 $308
1989-03-31 $386
1988-12-31 $388
1988-09-30 $330
1988-06-30 $350
1988-03-31 $364
1987-12-31 $366
1987-09-30 $379
1987-06-30 $380
1987-03-31 $396
1986-12-31 $395
1985-12-31 $239
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $495.141B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12